Global healthcare consulting and market research firm Kantar Health has launched CancerLandscape, which offers fast navigation of large datasets to better understand oncology drug opportunities and the competitive landscape.

It is intended to help users to evaluate business development and licensing opportunities, identify novel targets for drug development, compare company pipelines and understand the competitive landscapes in multiple tumour types.

"For the first time, we've aggregated multiple data sources to achieve unprecedented insight that will help identify the tumours that may be of greatest interest for investment or resource deployment," said Cory Lewis, manager, oncology commercial development, Kantar Health.

"CancerLandscape combines the breadth of Big Data with the depth of our large team of Ph.D.-level oncology experts who have the clinical and commercial expertise to provide actionable insights.

"Our oncology expertise that people have come to trust has been put into the development of CancerLandscape to provide our clients with the information they need to make the best decisions in one place where they can view the entire cancer landscape."

CancerLandscape lets users review more than 2,000 cancer drugs covering more than 175 tumour types. It tracks every oncology medicine in development by company, mechanism of action, tumour type, geography and stage of clinical development.